US Drug Recall Register
Class II · Moderate risk Terminated Initiated Oct 26, 2021 (5 years ago)

Maximum Strength No Drip Nasal Spray

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Products were manufactured with contaminated excipient that was recalled from the excipient supplier.

What was recalled

Maximum Strength No Drip Nasal Spray, Oxymetazoline HCl 0.05% Nasal Decongestant, 1 FL Oz (30 mL) per bottle, DISTRIBUTED BY: RITE AID, 30 HUNTER LANE, CAMP HILL, PA 17011. NDC 11822-6319-1

Recalling firm
Perrigo Company PLC
NDC code
11822-6319-1
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0621-2022

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Oxymetazoline recalls

See all
Class III · Low risk Ongoing

SinuFrin Decongestant

Reason Sub-potent Drug

Neilmed Pharmaceuticals Inc NDC 13709-325-01 D-0569-2024
Class II · Moderate risk Ongoing

Quality Choice No Drip Severe Congestion Nasal Pump Mist

Reason CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the manufacturing of the products. No contamination was found in the final products.

Seaway Pharma Inc. NDC 63868-608-01 D-0217-2024
Class II · Moderate risk Ongoing

Quality Choice No Drip Extra Moisturizing Nasal Pump Mist…

Reason CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the manufacturing of the products. No contamination was found in the final products.

Seaway Pharma Inc. NDC 63868-676-01 D-0216-2024
Class II · Moderate risk Ongoing

Nasal Spray Original No Drip Oxymetazoline HCl Nasal Solution

Reason CGMP Deviations: Firm reported possible microbial contamination in the purified water used in the manufacturing of the products. No contamination was found in the final products.

Seaway Pharma Inc. NDC 63868-607-01 D-0214-2024